Toronto-based Biossil has raised $153M in a funding round led by OpenAI, valuing the AI-driven drug revival startup at $1B.
TL;DR
- Biossil secures $153M in OpenAI-led funding, reaching a $1B valuation.
- The startup uses AI to identify and revive failed drug candidates, potentially saving years of research and millions in costs.
- Biossil's approach could accelerate drug development and reduce costs, addressing critical healthcare needs.
What happened
OpenAI led a $153M venture capital financing round in Biossil, a Toronto startup that uses AI to revive failed drug candidates. This round values Biossil at $1B. OpenAI contributed the majority through its OpenAI Startup Fund. Founders Fund, led by Peter Thiel, also participated, along with existing investors and new backers like Duke University's endowment fund and Abu Dhabi Investment Council.
Biossil plans to use the funding to expand its clinical development capacity and acquire more drug candidates. The deal is all-equity, with a small portion allocated to early employees. The company recently created a new class of preferred shares valued at $28.69 each, triple the value of shares issued in the previous financing round.
Why it matters
Biossil's AI-driven approach could significantly accelerate drug development by reviving abandoned candidates, potentially saving years of research and millions in costs. This could address critical healthcare needs, particularly for diseases like sickle cell disease and glioblastoma.
The investment underscores OpenAI's expanding focus on sector-specific AI tools, particularly in healthcare. This move comes as AI companies face increasing scrutiny over the broader societal impacts of their technologies. By investing in healthcare applications, OpenAI and other AI giants aim to demonstrate the positive potential of AI.
Key facts
- Biossil raises $153M in OpenAI-led funding round.
- Biossil valued at $1B post-funding.
- OpenAI Startup Fund provides majority of the investment.
- Founders Fund, Duke University's endowment fund, and Abu Dhabi Investment Council among investors.
- Biossil plans to expand clinical development and acquire more drug candidates.
- New preferred shares valued at $28.69 each, triple the value of previous shares.
- Biossil has partnered with leading institutions like SickKids, Harvard, and the Mayo Clinic.
- The startup has licensed or acquired 12 molecules, including a precision antibiotic from Summit Therapeutics.
Context
Biossil was co-founded in 2023 by Anthony Mouchantaf, a former RBC venture capital strategist, and Alexander Mosa, a trained internal medicine specialist. The company's unique approach involves using AI to scavenge through failed drug candidates and identify ways to modify and revive them.
This strategy differs from other AI-driven drug development companies, which focus on designing new molecules from scratch. Biossil's method could potentially bring life-saving therapies to market faster and at a lower cost.
The investment in Biossil comes as AI companies like OpenAI and Anthropic expand into sector-specific applications. Anthropic recently launched a wet laboratory in the San Francisco Bay Area, using its Claude AI assistant to accelerate life-sciences research.
